Lenalidomide

• CAT Number: I002458
• CAS Number: 191732-72-6
• Molecular Formula: C13H13N3O3
• Molecular Weight: 259.3
• Purity: ≥95%
• Synonyms: 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
• Target: TNF-α
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: Store at -20°C
• IC50: 13 nM
• InChI: InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
• InChIKey: GOTYRUGSSMKFNF-UHFFFAOYSA-N
• SMILES: NC1=C(CN(C2C(NC(CC2)=O)=O)C3=O)C3=CC=C1

Lenalidomide (CAT: I002458) is a medication used in the treatment of various cancers, including multiple myeloma and certain types of lymphoma. It is also used in the management of myelodysplastic syndromes and mantle cell lymphoma. Lenalidomide belongs to a class of drugs known as immunomodulatory agents, which have both anti-cancer and immunomodulatory effects. It works by enhancing the immune system’s response to cancer cells and inhibiting the growth of abnormal cells. Lenalidomide is usually taken orally and may be used in combination with other cancer treatments. Common side effects may include fatigue, nausea, diarrhea, and decreased blood cell counts.

Overview of Clinical Research

Lenalidomide is an angiogenesis inhibitor and an apoptosis stimulant developed by Celgene Corporation. Celgene completed a phase II trial in Mulyiple myeloma in France in 2020.

Reference

1:Lenalidomide/Melphalan/Dexamethasone in newly diagnosed patients with AL Amyloidosis: results of a prospective phase 2 study with long-term follow-up. Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.Haematologica. 2017 May 18. pii: haematol.2016.163246. doi: 10.3324/haematol.2016.163246. [Epub ahead of print] PMID: 28522573
2:Maintenance Lenalidomide for Large-Cell Lymphoma: Who Really Benefits? Witzig TE.J Clin Oncol. 2017 May 17:JCO2017732578. doi: 10.1200/JCO.2017.73.2578. [Epub ahead of print] No abstract available. PMID: 28514184
3:Successful treatment of bortezomib-refractory multiple myeloma derived from monoclonal gammopathy of undetermined significance with dose-adjusted lenalidomide therapy in a patient with concomitant end-stage renal disease due to diabetic nephropathy requiring haemodialysis. Kawano N, Yokota-Ikeda N, Minoda K, Hashiguchi H, Yoshida S, Kuriyama T, Yamashita K, Miyazaki Y, Inoue S, Shimao Y, Kodama K, Uezono S, Ueda A.CEN Case Rep. 2014 May;3(1):24-29. doi: 10.1007/s13730-013-0078-x. Epub 2013 Jul 23. PMID: 28509247 Free PMC Article
4:Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma. Maharaj S, Chang S, Seegobin K, Serrano-Santiago I, Zuberi L.Expert Rev Anticancer Ther. 2017 May 16. doi: 10.1080/14737140.2017.1330153. [Epub ahead of print] PMID: 28508703
5:Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. Khouri MR, Jabbour EJ, Gulbis AM, Turturro F, Ledesma C, Korbling M, Samuels BI, Ahmed S, Alousi AM, Ciurea SO, Marin D, Patel KK, Popat UR, Bueso-Ramos CE, Bassett RL Jr, Khouri IF.Biol Blood Marrow Transplant. 2017 May 8. pii: S1083-8791(17)30445-7. doi: 10.1016/j.bbmt.2017.04.027. [Epub ahead of print] PMID: 28495642
6:Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.Cancer Chemother Pharmacol. 2017 May 9. doi: 10.1007/s00280-017-3323-8. [Epub ahead of print] PMID: 28488026
7:Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.J Clin Oncol. 2017 May 9:JCO2015662510. doi: 10.1200/JCO.2015.66.2510. [Epub ahead of print] PMID: 28486043
8:Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG.Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14733. [Epub ahead of print] PMID: 28485007
9:A Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R.Blood. 2017 May 8. pii: blood-2016-09-740787. doi: 10.1182/blood-2016-09-740787. [Epub ahead of print] PMID: 28483761
10:Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO.Leuk Lymphoma. 2017 May 9:1-4. doi: 10.1080/10428194.2017.1312382. [Epub ahead of print] No abstract available. PMID: 28482750